Details

Autor(en) / Beteiligte

• Xu, Yan
• Si, Qing-tu-na-la
• Zhang, Man-hua
• Jiao, Jian
• Zhang, Yong-gui
• Ji, Shang-wei
• Zhao, Ping
• Guo, Hong-hua
• Li, Yan
• Zhou, Chang-yu
• Wang, Jiang-bin

Titel

Clinical antiviral effects of Peg-IFNa-2a in patients with chronic hepatitis B

Ist Teil von

• Zhonghua gan zang bing za zhi, 2011-09, Vol.19 (9), p.670

Ort / Verlag

China

Erscheinungsjahr

2011

Quelle

MEDLINE

Beschreibungen/Notizen

• To evaluate antiviral effects of Peg-IFNa-2a in patients with chronic hepatitis B. 92 chronic hepatitis B patients were enrolled to receive the treatment with Peg-IFNa-2a 180 μg subcutaneous injection once weekly. The patients who did not get early response were divided into 3 groups: group 1, extend the treatment to 72 weeks; group 2, combined with nucleus(s)ide analogue (entecavir or adefovir) treatment; group 3, continue the treatment until 48 weeks. HBV DNA and quantitative HBsAg were assessed at baseline, week 12, 24, 36 and after 24 weeks follow-up. Patients in group 1 had significantly higher SVR rate (78.3%) than patients in group 3 (38.1%, X2=7.33, P<0.05). The mean reduction of HBsAg in group 1 at 24 weeks of post-treatment follow up was higher than that in group 3 (t=2.11, P<0.05). In group 2 the mean reductions of HBV DNA at 24 weeks of post-treatment follow up were (3.9+/-1.1) log10 copy/ml and (3.7+/-1.3) log10 copy/ml respectively with combination of entecavir or adefovir, both of which were si